组织学与内镜联合终点与乌司奴单抗治疗溃疡性结肠炎疗效的关系
基于UNIFI 3期研究2630份结肠活检,评估组织学改善与内镜改善联合终点(组织学-内镜黏膜愈合)与临床结局的关系。诱导后达到组织学-内镜黏膜愈合者第44周临床缓解率61%(56/92),高于单独内镜改善的39%(9/23,P=0.0983)或单独组织学改善的34%(24/71,P=0.0009)。
要点
- 组织学改善与临床缓解、较低疾病活动度显著相关(P<.0001)。
- 更严格组织学改善定义下,乌司奴单抗第8周和第44周组织学改善率显著高于安慰剂。
- 诱导后组织学-内镜黏膜愈合者第44周临床缓解率高于单独组织学或内镜改善者。
核心结论
- UNIFI项目数据表明,诱导治疗后达到组织学-内镜黏膜愈合与维持治疗结束时较低的疾病活动度相关,优于单独组织学改善或单独内镜改善。
研究设计与样本
- 对UNIFI 3期溃疡性结肠炎临床研究中乌司奴单抗治疗患者的2630份结肠活检样本评估组织学疾病活动度。
- 分析组织学改善与诱导结束(第8周和第16周)及维持(第44周)临床终点的关联。
- 评估组织学与内镜(Mayo内镜子评分0或1)联合改善终点(称为组织学-内镜黏膜愈合或组织学-内镜黏膜改善)的有效性。
主要发现
- 组织学改善与临床缓解、较低平均疾病活动度评分及疾病活动度更大改善显著相关(P<.0001)。
- 采用更严格组织学改善定义时,乌司奴单抗诱导第8周和维持第44周组织学改善率显著高于安慰剂。
- 诱导后组织学改善和内镜改善与第44周组织学-内镜黏膜愈合、临床缓解及无糖皮质激素缓解率提高10%至20%相关(所有P<.05)。
- 第44周,诱导后达到组织学-内镜黏膜愈合者临床缓解率为61%(56/92),单独内镜改善者为39%(9/23,P=0.0983),单独组织学改善者为34%(24/71,P=0.0009)。
关键数值与推荐
- 组织学改善定义为隐窝中性粒细胞浸润小于5%且无隐窝破坏、糜烂、溃疡或肉芽组织。
- 内镜改善定义为Mayo内镜子评分0或1。
- 组织学-内镜黏膜愈合定义为组织学改善联合内镜改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Ustekinumab induces and maintains histologic improvement in patients with ulcerative colitis (UC). The clinical relevance of this endpoint alone, and in combination with endoscopic improvement, is unknown. METHODS: Histologic disease activity was evaluated in 2630 colonic biopsy samples from patients with UC treated in the UNIFI phase 3 UC clinical studies of ustekinumab. We evaluated associations between histologic improvement (defined as the composite of neutrophil infiltration in less than 5% of crypts and no crypt destruction, erosions, ulcerations, or granulation tissue) and clinical endpoints at the end of induction (week 8 and 16) and maintenance (week 44) periods. We assessed the validity of a combined histologic and endoscopic (Mayo endoscopy subscore, 0 or 1) improvement endpoint, which we called histo-endoscopic mucosal healing (or histo-endoscopic mucosal improvement). RESULTS: Histologic improvement was significantly (P < .0001) associated with clinical remission, lower mean disease activity scores, and greater improvement in disease activity at the end of induction and maintenance studies. Ustekinumab induced and maintained significantly higher rates of histologic improvement at induction week 8 and maintenance week 44 than placebo when more stringent definitions of histologic improvement were used. Histologic improvement and endoscopic improvement following induction were associated with 10% to 20% higher rates of histo-endoscopic mucosal healing, clinical remission, and corticosteroid-free remission at week 44 (all P < .05) in patients who received ustekinumab maintenance therapy. At week 44, 61% of patients (56/92) with histo-endoscopic mucosal healing after induction therapy achieved clinical remission, versus 39% of patients (9/23, P = .0983) and 34% of patients (24/71, P = .0009) with endoscopic or histologic improvement alone after induction, respectively. CONCLUSION: Data from the UNIFI program of ustekinumab in patients with UC treated with ustekinumab indicated the achievement of histo-endoscopic mucosal healing after induction therapy is associated with lower disease activity at the end of maintenance therapy than either histologic or endoscopic improvement alone. ClinicalTrials.gov number: NCT02407236.
引用
- Li K, Marano C, Zhang H, et al. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020. PMID: 32853634. doi:10.1053/j.gastro.2020.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。